CONCORD, Calif.--(BUSINESS WIRE)--
Cerus Corporation (NASDAQ: CERS) announced today that the National
Transfusiology Center (NTC) of Mongolia has signed a purchase agreement
for the INTERCEPT Blood System for platelets and plasma. The agreement
is part of a national tender awarded to Cerus’ Mongolian distributor,
Inter Science LLC, for the supply of blood bank equipment.
“We are honored that INTERCEPT has been chosen by the National
Transfusiology Center of Mongolia as part of an important initiative to
improve blood transfusion safety,” commented Pascal Maillard, Cerus’
Vice President for Asia. “INTERCEPT’s pathogen inactivation technology
represents a leap forward for patients receiving care through the
Mongolian health care system.”
The NTC aims to improve the safety of individuals working in and
receiving care through the Mongolian health care system, with a mission
to improve the safety of blood transfusions, strengthen medical waste
management, and prevent and control hospital acquired infections.
Mongolia has one of the highest rates of hepatitis B and C in the world,
with insufficient blood transfusion and waste management practices
contributing to additional rates of infection.
The NTC will complete several system and equipment modifications through
2017 as part of the Fifth Health Sector Development Project (FifHSDP), a
partnership between the Ministry of Health and Sports of Mongolia and
the Asian Development Bank to technologically improve health care
facilities across Mongolia.
ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field
of blood transfusion safety. The INTERCEPT Blood System is designed to
reduce the risk of transfusion-transmitted infections by inactivating a
broad range of pathogens such as viruses, bacteria and parasites that
may be present in donated blood. The nucleic acid targeting mechanism of
action of the INTERCEPT treatment is designed to inactivate established
transfusion threats, such as Hepatitis B and C, HIV, West Nile Virus and
bacteria, as well as emerging pathogens such as chikungunya, malaria and
dengue. Cerus currently markets and sells the INTERCEPT Blood System for
both platelets and plasma in the United States, Europe, the Commonwealth
of Independent States, the Middle East and selected countries in other
regions around the world. The INTERCEPT red blood cell system is in
clinical development. See http://www.cerus.com
for information about Cerus.
INTERCEPT and INTERCEPT Blood System are trademarks of Cerus Corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151210005669/en/
Source: Cerus Corporation